Utilities Registry

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Valuation

Population

Condition

Viewing 1 - 10 of 44 results

Title	Year(s) of data collection	Valuation Method	Country	Condition
Selection of neurological disease health state utilities (Gebrehiwet P et al., J Med Econ. 2023. doi:10.1080/13696998.2023.2192588)	2017 - 2019	EQ-5D-5L	Australia, Canada, Ireland, Netherlands, Spain, United States of America	Amyotrophic lateral sclerosis
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics 456 participants with clinical trial data from FORTITUDE-ALS that evaluated reldesemtiv versus placebo in patients with ALS
Title Selection of oncology health state utilities (Chu YR et al., Integr Cancer Ther. 2023. doi:10.1177/15347354221150907)	Year(s) of data collection 2018 - 2019	Valuation Method EQ-5D	Country Taiwan (Province of China)	Condition Breast cancer
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 450 breast cancer patients treated with and without adjunctive traditional Chinese medicine
Title Selection of oncology health state utilities (Konara Mudiyanselage SP et al., Breast Cancer. 2023. doi:10.1007/s12282-022-01413-6)	Year(s) of data collection 2010 - 2021	Valuation Method EQ-5D	Country Taiwan (Province of China)	Condition Breast cancer surgery
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics A cohort of 741 women who underwent a mastectomy and breast reconstruction
Title Selection of autoimmune disease health state utilities (Chung MP et al., Rheumatology (Oxford). 2022. doi:10.1093/rheumatology/keab810)	Year(s) of data collection 2016 - 2020	Valuation Method SF-6D	Country United States of America	Condition Calcinosis in systemic sclerosis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 12 participants from a prospective, single-arm, open-label, dose-escalation trial
Title Selection of oncology health state utilities (Katanyoo K et al., Expert Rev Pharmacoecon Outcomes Res. 2022. doi:10.1080/14737167.2021.1906224)	Year(s) of data collection 2019	Valuation Method EQ-5D-3L, EQ-5D-5L, TTO	Country Thailand	Condition Cervical cancer
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 194 cross-sectional study patients with locally advanced cervical cancer
Title Selection of neurological disease health state utilities (Janssen N et al., J Alzheimers Dis. 2022. doi:10.3233/JAD-215304)	Year(s) of data collection 2009 - 2011	Valuation Method SF-6D	Country Finland	Condition Cognitive decline
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics 1120 participants with longitudinal 2-year data from the FINGER study to investigate the association between cognition, health related quality of life, and costs in a population at risk for cognitive decline
Title Selection of COVID-19 health state utilities (Philip KEJ et al. Lancet Respir Med. 2022. doi:10.1016/S2213-2600(22)00125-4)	Year(s) of data collection 2021	Valuation Method SF-6D	Country United Kingdom of Great Britain and Northern Ireland	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 150 people in RCT of breathing and wellbeing programme for people with persistent symptoms following COVID-19
Title Selection of COVID-19 health state utilities (Rosa RG et al., Intensive Care Med. 2023. doi:10.1007/s00134-022-06953-1)	Year(s) of data collection 2020 - 2022	Valuation Method EQ-5D-3L	Country Brazil	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 1156 adults post-hospitalization COVID-19 patients
Title Selection of COVID-19 health state utilities (Granholm A et al. Acta Anaesthesiol Scand 2023. doi:10.1111/aas.14231)	Year(s) of data collection 2020 - 2021	Valuation Method EQ-5D-5L	Country Denmark, India, Sweden, Switzerland	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 982 patients in COVID STEROID 2 trial
Title Selection of COVID-19 health state utilities (Chakravarty R et al., Indian J Psychol Med. 2023. doi:10.1177/02537176221140557)	Year(s) of data collection 2021	Valuation Method EQ-5D-5L	Country India	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 80 COVID-19 patients treated with single infusion tocilizumab or no treatment

Next results →